Newron Pharmaceuticals S.p.A. (NWPHF)
OTCMKTS · Delayed Price · Currency is USD
12.00
+0.60 (5.26%)
May 15, 2024, 9:30 AM EDT

Newron Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
May '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
353192105303243
Upgrade
Market Cap Growth
87.56%83.21%250.69%-5.67%-26.87%-62.94%
Upgrade
Enterprise Value
364231140473827
Upgrade
Last Close Price
9.369.365.222.102.102.44
Upgrade
PE Ratio
11.8511.72----
Upgrade
PS Ratio
5.013.6110.484.594.846.74
Upgrade
PB Ratio
189.74127.32-3.17-1.998.982.06
Upgrade
P/TBV Ratio
189.86127.32--8.982.06
Upgrade
EV/Sales Ratio
5.184.3413.957.265.774.13
Upgrade
EV/EBITDA Ratio
8.778.52----
Upgrade
EV/EBIT Ratio
8.818.53----
Upgrade
Debt / Equity Ratio
33.2334.62-1.62-3.2513.871.53
Upgrade
Debt / EBITDA Ratio
1.491.91----
Upgrade
Asset Turnover
1.391.150.290.140.110.09
Upgrade
Quick Ratio
1.402.420.625.5010.585.50
Upgrade
Current Ratio
1.512.600.685.6510.795.50
Upgrade
Return on Equity (ROE)
-----146.43%-77.71%
Upgrade
Return on Assets (ROA)
50.97%36.44%-23.05%-18.96%-15.19%-20.26%
Upgrade
Return on Capital (ROIC)
60.97%46.45%-28.99%-21.37%-17.21%-23.21%
Upgrade
Return on Capital Employed (ROCE)
165.20%64.80%----
Upgrade
Earnings Yield
8.44%8.54%-17.09%-62.50%-53.44%-59.23%
Upgrade
FCF Yield
8.17%-9.50%-10.70%-39.69%-41.12%-44.07%
Upgrade
Buyback Yield / Dilution
-16.86%-15.30%----
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.